On this page
Behçet disease
This complex condition causes episodes of inflammation throughout the body, most commonly affecting the mouth, genitals, eyes, skin, and blood vessels. Severity varies considerably, from mild recurrent ulcers to sight-threatening eye disease or major vascular complications. Prevalence is highest along the historic Silk Road trade route.
Overview
Behçet disease represents a systemic autoinflammatory disorder in which the immune system triggers unpredictable episodes of inflammation across multiple organ systems without clear external triggers. Unlike autoimmune conditions that target specific tissues, Behçet disease involves vasculitis - inflammation of blood vessels of all sizes throughout the body. The hallmark clinical features include painful mouth sores that recur repeatedly, similar ulcers affecting the genital area, and inflammation within the eye that can threaten vision if untreated.
Prevalence varies dramatically by geography and ancestry. The condition is most common in countries along the historic Silk Road, including Turkey, Iran, Japan, Korea, and parts of the Mediterranean basin. In the United Kingdom and Northern Europe, Behçet disease is considerably rarer. Men and women are affected, though some evidence suggests men may experience more severe vascular and neurological complications whilst women may have more prominent mucocutaneous features.
The episodic nature of Behçet disease means that symptoms typically flare and subside over time rather than following a steadily progressive course. Some individuals experience relatively mild disease with intermittent ulcers and manageable discomfort, whilst others develop serious complications affecting the eyes, central nervous system, or major blood vessels requiring intensive specialist care.
Symptoms & clinical features
The majority of individuals with Behçet disease first notice recurrent painful mouth ulcers, which often appear identical to common aphthous ulcers but occur with greater frequency and severity. These oral lesions typically develop on the tongue, lips, gums, or inside the cheeks, may be single or multiple, and usually heal within one to three weeks before recurring. Genital ulcers are a common feature of the condition, appearing on the scrotum or penis in men and the vulva or vagina in women, often leaving scars after healing.
Eye involvement occurs frequently and represents one of the most serious manifestations. Inflammation may affect the uvea (the middle layer of the eye), retina, or associated blood vessels, causing eye pain, blurred vision, light sensitivity, floaters, or redness. Without prompt treatment, recurrent eye inflammation can lead to permanent vision loss. Skin manifestations vary widely and may include acne-like lesions, nodules resembling erythema nodosum typically on the legs, or pustules. Many individuals exhibit pathergy - an exaggerated skin reaction to minor trauma such as needle pricks, which clinicians sometimes use as a diagnostic sign.
Vascular complications affect veins more commonly than arteries and may cause blood clots in deep leg veins, inflammation of superficial veins, or rarely aneurysms in major arteries. Joint pain and swelling, typically affecting knees, ankles, wrists, or elbows, occurs in many cases. Gastrointestinal involvement, more frequent in Japanese populations, can cause abdominal pain, diarrhoea, and ulcers throughout the digestive tract. Neurological manifestations, though less common, may include headaches, meningoencephalitis, or stroke-like episodes affecting cognition or motor function.
Video: Genetics 101
Affected organs
The defining feature of Behçet disease is its ability to affect blood vessels throughout the body, from tiny capillaries to large veins and arteries. This vasculitis underlies most of the condition's diverse manifestations. The oral and genital mucous membranes bear the most consistent impact, with recurrent ulceration causing significant discomfort and potential scarring. The eyes experience inflammation that may involve the anterior chamber, uveal tract, retina, or retinal blood vessels, with posterior uveitis and retinal vasculitis carrying the greatest risk of vision impairment.
The skin serves as both a target and diagnostic indicator, displaying various inflammatory lesions and the characteristic pathergy response. Veins throughout the body, particularly in the legs, may develop thrombophlebitis or deep vein thrombosis. The gastrointestinal tract can develop ulcers resembling inflammatory bowel disease, most commonly in the ileocaecal region. The central nervous system, when affected, may show inflammation of the brainstem, meninges, or cerebral parenchyma. Joints experience non-erosive inflammatory arthritis. The cardiovascular system occasionally develops arterial aneurysms or thromboses that constitute medical emergencies.
Risks & severity
Disease severity exists along a broad spectrum. Some individuals experience primarily mucocutaneous disease with recurrent ulcers causing intermittent discomfort but no major organ damage. Others develop sight-threatening posterior uveitis, major vessel vasculitis with aneurysm formation, central nervous system involvement with potential for permanent neurological disability, or severe gastrointestinal disease requiring surgical intervention.
Age of onset typically falls between 20 and 40 years, though the condition can begin in childhood or later adulthood. Disease activity often fluctuates over time, with some individuals experiencing gradually decreasing symptom frequency after years of active disease. Eye disease requires particular vigilance, as repeated inflammatory episodes cause cumulative damage even when individual flares resolve. Vascular complications, whilst less common, carry significant morbidity and mortality risk. Male sex, younger age at onset, and certain genetic factors may correlate with increased likelihood of severe manifestations, though individual disease courses remain difficult to predict.
Genetic causes
Behçet disease demonstrates complex inheritance involving multiple genetic and environmental factors rather than following a simple Mendelian pattern. The condition does not result from a single gene mutation but rather arises when numerous genetic variants interact with environmental triggers. One of the strongest genetic associations involves the HLA-B51 allele, though this marker alone neither causes the disease nor is required for diagnosis.
Recent research has identified rare variants in IL10 associated with increased susceptibility in some families. This gene encodes interleukin 10, a crucial anti-inflammatory cytokine. Under normal circumstances, this signalling molecule dampens immune responses by suppressing pro-inflammatory cytokine production, modulating T cell activity, and maintaining immune balance. When pathogenic variants compromise IL10 function, these regulatory mechanisms may fail, potentially permitting uncontrolled inflammatory cascades. Such dysregulation could contribute to the vasculitis and tissue damage observed in Behçet disease.
Other genes implicated in disease susceptibility include those involved in innate immunity, cytokine signalling, and endothelial function, though each contributes modest individual risk. The polygenic nature means that genetic testing currently has limited clinical utility for diagnosis, which relies instead on characteristic clinical features. Environmental factors, including certain infections and geographical location, likely interact with genetic predisposition to trigger disease onset in susceptible individuals.
Inheritance pattern
Behçet disease does not follow a straightforward inheritance pattern such as autosomal dominant or recessive. Instead, the condition represents a complex trait influenced by multiple genes, each contributing small effects, combined with environmental factors. Family clustering does occur - evidence suggests that having a first-degree relative with Behçet disease elevates one's risk substantially compared to the general population - but the majority of affected individuals have no family history.
Children of an affected parent face an elevated but still relatively low absolute risk of developing the condition. Because multiple genetic variants across different chromosomes contribute to susceptibility, siblings of affected individuals do not have the 25 or 50 percent recurrence risks seen in classic Mendelian disorders. Genetic counselling can help families understand their specific situation, though precise risk figures remain difficult to calculate given the polygenic architecture and the significant role of non-genetic factors in disease expression.
Diagnosis & testing
Diagnosis rests primarily on clinical criteria, as no single definitive laboratory test confirms Behçet disease. Clinicians typically apply the International Study Group criteria, which require recurrent oral ulceration (at least three episodes in twelve months) plus two of the following: recurrent genital ulceration, eye lesions (anterior or posterior uveitis or retinal vasculitis), skin lesions (erythema nodosum, pseudofolliculitis, papulopustular lesions, or acne in post-adolescent patients not on corticosteroids), or a positive pathergy test.
Genetic testing does not currently form part of routine diagnostic evaluation, as the polygenic nature and variable penetrance of associated variants limit their predictive value. Laboratory investigations help exclude mimicking conditions and assess disease activity but yield no pathognomonic findings. Blood tests may show elevated inflammatory markers during flares. Tissue biopsy of ulcers or skin lesions typically reveals non-specific inflammation. In the UK, referral to clinical immunology or rheumatology services often follows initial suspicion by general practitioners or ophthalmologists. For individuals meeting diagnostic criteria, NHS care pathways involve multidisciplinary input from rheumatology, ophthalmology, dermatology, and other specialists depending on organ involvement.
Management & lifestyle
Management focuses on controlling inflammation during active disease episodes, preventing flares, and protecting organs at risk of irreversible damage, particularly the eyes. Treatment selection depends on disease severity and which organs are affected. Mild mucocutaneous disease may respond to topical corticosteroids for ulcers and colchicine, which some evidence suggests reduces ulcer frequency. More significant disease often requires systemic immunosuppression.
Moderate to severe manifestations typically warrant systemic corticosteroids during acute flares, often combined with disease-modifying agents such as azathioprine, which has demonstrated efficacy in preventing eye disease progression. For severe posterior uveitis threatening vision, biologics targeting tumour necrosis factor alpha (such as infliximab or adalimumab) have shown benefit in clinical trials. Anticoagulation requires careful consideration in vascular involvement, as the optimal approach for venous thrombosis in the setting of active vasculitis differs from standard protocols.
Regular ophthalmology monitoring is essential for anyone with eye involvement or risk factors for ocular disease. NHS care typically coordinates through specialist centres with experience managing Behçet disease. Genetic counselling services can address family planning questions and explain inheritance patterns to affected individuals and their relatives. Lifestyle modifications have limited evidence base, though some patients report symptom triggers such as stress or specific foods. Dental care to minimise oral trauma and good genital hygiene may help reduce ulcer frequency in some individuals.
UK care pathway
Within the NHS, suspected Behçet disease usually prompts referral to rheumatology or clinical immunology services, often coordinated with ophthalmology if eye symptoms are present. Specialist centres with multidisciplinary expertise in vasculitis and rare autoinflammatory conditions provide optimal care for complex cases. The condition does not currently feature on the NHS Genomic Medicine Service rare disease panels, reflecting its polygenic nature and the limited role of genetic testing in diagnosis.
Genetic counselling remains available through regional genetics services for families seeking to understand recurrence risks or inheritance patterns. Access to specialist nursing support, patient information resources, and links to support organisations forms part of comprehensive care. For those with severe manifestations requiring biologic therapies, shared care arrangements between specialist centres and local hospitals often facilitate ongoing treatment whilst maintaining expert oversight.
Frequently asked questions
Will my children develop Behçet disease if I have it?
The risk is elevated but remains relatively low. Having a parent with Behçet disease does increase a child's risk compared to the general population, but because the condition is uncommon in the UK and depends on multiple genetic and environmental factors, most children of affected parents will not develop the disease.
Can Behçet disease be cured?
There is currently no cure, but treatment can effectively control symptoms and prevent serious complications in most people. Many individuals experience decreasing disease activity over time, and modern therapies - particularly for eye disease - have significantly improved long-term outcomes.
How often will I need eye examinations?
If you have eye involvement or are at risk based on disease severity, ophthalmology monitoring every three to six months is typical, though your specialist may adjust this based on disease activity. Prompt attention to any new visual symptoms between scheduled appointments is essential.
Are there dietary or lifestyle changes that help with Behçet disease?
Evidence for specific dietary interventions remains limited. Some people identify personal triggers such as certain foods or stress, and avoiding these may help reduce flare frequency. Maintaining good oral hygiene, avoiding unnecessary oral trauma, and not smoking are generally recommended.
Is Behçet disease an autoimmune condition?
Behçet disease is classified as autoinflammatory rather than autoimmune. Autoinflammatory conditions involve dysregulation of the innate immune system causing episodes of inflammation, whilst autoimmune diseases involve the adaptive immune system producing antibodies against the body's own tissues. This distinction affects how the condition is understood and treated.
References
- Davatchi F. Behçet's disease. International journal of rheumatic diseases. 2018. PMID: 30681276
- Davatchi F. Behcet's disease. International journal of rheumatic diseases. 2014. PMID: 24762121
- Krause I, Weinberger A. Vasculo-Behçet's disease. The Israel Medical Association journal : IMAJ. 2002. PMID: 12183873
- Sakane T, Takeno M, Suzuki N. Behçet's disease. The New England journal of medicine. 1999. PMID: 10528040
- Zhang L, Wang X, Liu F. Neuro-Behcet disease. Archives of medical science : AMS. 2021. PMID: 33747296
- Stratigos AJ, Laskaris G, Stratigos JD. Behçet's disease. Seminars in neurology. 1992. PMID: 1485044
- Behçet's disease. Lancet (London, England). 1989. PMID: 2564568
- Kim DY. Mortality landscape of Behçet disease. The British journal of dermatology. 2024. PMID: 38469625